Bio Generics & India

38
1 Biogenerics & India

description

all info is compiled, from public domain sources

Transcript of Bio Generics & India

Page 1: Bio Generics & India

1

Biogenerics & India

Page 2: Bio Generics & India

2

Contents• Biologics

• Biogenerics

• Biotechnology & India• Market Outlook• Leading Products• Pipeline

• Introduction• Market • Issues• Patent Status• Development Portfolio

• Biogenerics• Factors• Advantages• Target Biogenerics• Indian Manufacturers

& Pipeline

• Regulatory – ScenarioUS, EU & India

Page 3: Bio Generics & India

3

Biologics - BackgroundGlobal biologics market is estimated to be ~$ 53 billion (excluding vaccines) constituting ~9% of global pharmaceutical market.

~125 biologics currently marketed.

The research and development costs associated with biologics are high because biologics are structurally complex and difficult to manufacture.

Genentech, estimated that it has invested $6.4 billion in research over the last 28 years.

These high costs are then passed on to consumers, who often foot bills for biologic treatments ranging anywhere from $10,000 to $25,000 a year. In some rare cases, costs can exceed $170,000 per year.

Page 4: Bio Generics & India

4

Biologics constituted ~9.4% of the total biopharmaceutical market

$12.18

$32.80

$549

$4.43

$3.43

•US is the largest market for biologics with >60% of global biotherapeutic sales, ROW constitutes ~8%

Sales Estimates – 2005Sales Estimates – 2005

US

EU

Japan

ROW

$ 52.84$ 549

$ 32.80

$ 12.18

$ 3.83

$ 4.43

Page 5: Bio Generics & India

5

But the growth of biotech has continuously outpaced that of pharmaceuticals

0%

5%

10%

15%

20%

25%

30%

2000 2001 2002 2003 2004 2005

YoY

Grow

th in

%

Pharmaceuticals Biologics

•23% of total industry growth in 2004 came from biotech products

Ref:: IMS Industry in Figures 2005; Stratycon Estimates

Page 6: Bio Generics & India

6

Erythropoietin is the leading class of biologic constituting ~22% of biologic market (excl. vaccines)

10.9

7.67.2

6.8

3.8 3.8

2.3 2.2 2.11.3 1.1 1.0

0.0

2.0

4.0

6.0

8.0

10.0

12.0

2005

Glo

bal S

ales $

bio

.

Erythropoietins

TNF

Insulin & analogs

Cancer Antibodies

Interferon Beta

G-CSF

Human Growth Hormone

Rec. Coagulation Factors

Interferon Alpha

Enzyme Replacement

Antiviral Antibody

Follicle Stimulating Hormones

Page 7: Bio Generics & India

7

Leading Biotech Products

Product Compound2005 ww

Sales($ bio.)*

Growth (Y0Y) %

PEG/FILGRASTIM

Rituximab

Epoetin alfa

Darbepoietin alfa

Etanercept

Infliximab

Epoetin alfa

Epoetin beta

Trastuzumab

Interferon beta-1a

3.50

3.33

31.5%

22.0%

-7.0%

32.0%

42.0%

18.0%

-6.0%

8.0%

48.0%

8.90%

3.32

3.27

2.57

2.54

2.46

1.81

1.72

1.54

26.07

neulasta/neupogenmabthera/ rituxan

procrit/ eprex

aranesp

enbrel

remicade

epogen

neorecormon, epogin

herceptin

avonex

TOTAL OF TOP 10

Company

AMGEN

ROCHE/GENENTECH

j&j

AMGEN

AMGEN

j&j

AMGEN

ROCHE

ROCHE

BIOGEN IDEC

Page 8: Bio Generics & India

8

Monoclonal antibodies, gene therapy are constitute major proportion of biologic pipeline apart from vaccines

•>400 biologics in development constituting ~19% of all developments are biotech products

160

62

46

43

21

20

18

16

9

8

62

0 50 100 150 200

Others

Interleukins

Immune based therapy

Growth Factors

Interferons

Antisense

Cellular therapy

Recombinant Hormones/Proteins

Gene Therapy

Vaccines

mAbs

# of Biologic in Development by Category

# of Biologic in Development by Category

Page 9: Bio Generics & India

9

BioGenerics

The biogenerics market is tipped to reach $16bn (€11.9bn) by 2011.

Regulated markets are taking the next step for biosimilars. ROWcountries could act as a launch pad taking products subsequentlyto regulated markets.

The 'biogeneric' analysis problem, 2007

Page 10: Bio Generics & India

10

Differences between Chemical Entities and Biogenerics

Chemical entities Biogenerics

Well-defined, easy-to-characterize molecular structures with impurity profiles that depend on their synthetic route of manufacture

In vivo safety and efficacy are unrelated to product origin

Routine chemical analysis are not sufficient to compare a biogeneric to its originator product

The demonstration of approvabilityfor biogeneric differs from the standard generics approach as it is based on a comparability exercise rather than on demonstration of bioequivalence

Need to establish on a case by case basis.

Page 11: Bio Generics & India

11

A tentative classification of biological therapeutics

Class Example

Biotech products recombinant DNA technology; controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells; hybridoma and monoclonal antibody methods

Vaccines vaccines

Blood derivatives sera; immunoglobulins; coagulation factors; plasma; albumin; interleukins

Other products extracted from native (non-engineered) biological sources

insulin; heparin and derivatives; amino acids; antibiotics obtained through fermentation; hyaluronic acid

Page 12: Bio Generics & India

12

Biogeneric - Market Outlook

13 of the leading biologics achieved mega-blockbuster status (i.e.,

exceeded $2 billion in global sales).

Those biologics that lose patent protection open an emerging opportunity

for biogenerics.

Taking a global perspective, we see that a branded biologic priced at

$10,000 a year may cost just $2,000 to manufacture in the U.S. or

Europe.

The high prices of biologic therapies make it imperative that generic or

off-patent products be marketed as options for consumers after patent

and exclusivity protections for manufacturers have expired.

Europe is leading the biogeneric charge; seven biosimilars have launched

there and four more were recently approved.

Page 13: Bio Generics & India

13

Biogeneric - Market Outlook

Worldwide interest in biogenerics is gaining momentum and is

expected to reach $5.8 billion by 2012.

By 2013, at least 10 branded biologics with total sales of $15 billion

will be generic and prime targets for genericization.

But first such stumbling blocks as safety, access to innovators' key

intermediates, process controls, availability and access to bulk

materials, specifically designed and adapted analytical procedures and

validation studies must be addressed.

Also, biosimilars cannot currently be marketed in the US because there

is no pathway for them to reach the market.

Page 14: Bio Generics & India

14

Issues surrounding Biogenerics

Regulatory hurdles

Technical &

quality issues

Innovator woes

Newer products

Issues

Page 15: Bio Generics & India

15

Selected biologics with expired patent

Product Compound Expired

Filgrastim GM-CSF Amgen 2007

Engerix-B Hepatitis B Vaccine GSK 2006

G-CSF

Human Insulin

Growth hormone

t-PA

EPO-α

Growth Hormone

Growth Hormone

Interferon b1a

Interferon a2b

Human Insulin

2006

2005

2005

2005

2004

2003

2003

2003

2002

2001

Neupogen

Novolin

Protropin

Activase

Epogen, Procrit

Nutropin

Humatrope

Avonex

Intron A

Humulin

Company

Amgen

NovoNordisk

Genetech

Genentech/BI

Amgen/J&J/Sankyo

Genentech

Eli Lilly

Biogen

Schering Plough

Eli Lilly

Page 16: Bio Generics & India

16

Biologic Drugs Losing Patent Protection

Page 17: Bio Generics & India

17

Markets in which Biogenerics are currently marketed

Others 20%

Major EU13%Canada/ US

13%Pacific (ex

Japan)27%

Eastern Europre/Baltic (e.g Lithuania)

27%

Pacific (ex Japan)2%

Eastern Europre/Baltic (e.g Lithuania)

3%Major EU

42%

Others 5%

Canada/ US48%

Markets in which pipeline biosimilars are being targeted towards

Page 18: Bio Generics & India

18

5DMMDMShanthaBiotech

4DMDMWockhardt

3DMDDRL

5DDDDDScino Pharma

5DDMMMScigen

6

D

D

mAB

3

D

tPA

9

D

D

M

D

M

INF

7

D

M

M

M

HGH

3MDMPliva (+Mayne)

3DDStada

5MMMBioPartners/ LGLS

2DDBioGenerix

4MDGeneMedix

1MDragon

7MMDBiocon

526912Total

1Sandoz

4MDTeva/Sicor/BTG

Total Insulin CSFEPOCompany

Leading Generic Companies & their biogenerics portfolio

D: Developing, M: Marketing

Page 19: Bio Generics & India

19

Indian Biotechnology Market

The Indian biotech market has doubled in size in the past two

years, reaching a value of US$ 2.08 billion in 2006-07, compared to US$ 1.45 billion in 2005-06.

The Indian market currently accounts for a little over 1.1 per cent of the global biotech market.

Off the 50 odd biotech products 13 are available in India & 7 biotech drugs are indigenously developed and produced by Indian Companies.

1453

3596

225

268Bio-PharmaBio-Services

Bio-Agri

Bio-Industry Bio-Informatics

Biotech Industry Revenues - 2006-07(US$ million)

Page 20: Bio Generics & India

20

Biogenerics - IndiaCompanies in Indian generics universe have gross margins closer to 50%. This means that an Indian generics company could enter the market, manufacture the same product, and be content to sell it at $4,000-5,000, a 50–60% discount.

For example, last year Dr. Reddy’s launched a Biogeneric version of Roche’s Rituxan/Mabthera in the Indian market at Rs. 20,000 per vial, or approximately $505, a 50% discount to Roche’s price in India.

With additional entrants and lower-cost manufacturing, prices could be driven down further. For example, Wockhardt recently invested $38 million to build a facility capable of manufacturing 15% of the worldwide supply of biologics.

Major brands of Erythropoietin products have become key targets for biogenerics, after accounting for 18.7% ($12bn) of global pharmaceutical sales in 2006. Amgen's Aransep held 55% of the EPO market in 2006, typifying the rapid growth of long-acting products.

Page 21: Bio Generics & India

21

"All the biotech products produced by Indian companies are generic in nature.

India has a huge market potential for Biogenerics”.

Off the 50 odd biotech drugs 13 are available in India and sevenbiotech drugs are indigenously developed and produced by the Indian companies.

Typically the market potential in India for biogenerics has been in the range of 0.1 percent (EPO) to 0.2 percent of (Insulin) of the global market value based on the type and class of molecule.

India has over 130 home grown biopharmaceutical companies, manyof which are fully integrated.

The global market for Indian Biopharmaceutical companies have touched $ 1.5 Billion in revenues (2006) with CAGR of 27%.

Indian biogeneric companies on the threshold of globalization, 2007 (biospectrum)

Page 22: Bio Generics & India

22

Factors Driving Development of a Biogenerics Market

Multiple Patent expiries for biologics launched in the late 1980s/ early 1990s.

Considerable market size for these biologic products.

Technological advancements enabling ‘replication’ of biologic products.

Consumer interest in lower cost alternative to expensive brandedbiologics.

Biogenerics are becoming technologically feasible and economically necessary, therefore are gaining Regulatory andPolitical attention

Page 23: Bio Generics & India

23

Key advantagesAt present India is one of the major contributors in the world biogeneric market along with the china. Some of the that India has upon other countries in biogenerics are-

Highest number of US FDA approved plants outside the US.

Compliance with GCP guidelines is an rise with Indian

Companies.

Highly qualified human resource availability.

Low capital and operational cost.

Pharma sector highly competitive in bioprocessing skills.

Excellent genomic research opportunity.

Page 24: Bio Generics & India

24

Measures that are fueling rapid growth

Increase in partly public-funded biotechnology incubators and parks.

Increase in the private venture capital, fiscal incentives and tax

benefits for R&D and exports.

Streamlining of regulatory pathway and reduction in the approval

time by various regulatory agencies.

Active role of Indian Pharmacopoeia in issuing product specific

monographs.

Increased penetration of private health insurance.

Increase in the burden of diseases (especially lifestyle diseases).

Increase in per capita pharmaceutical spend.

Modernization and integration of patents and other intellectual-

property offices with adoption of electronic filing system.

Page 25: Bio Generics & India

25

Protein Classes in which biogenerics are in development•Biogeneric Development has extended into protein classes with high market potential.

Coagulation Factors

7%

Interferon Gamma5%

Interferon Beta10%

IGF2%

FGF2%

Insulin3%GM-CSF

3%PTH5%

EGF2%

Interleukin3%

Erythropoietin 16%

G-CSF20%

Human Growth Hormone

12%

Interferon Alpha 10%

Biogeneric companies do not focus on providing merely copies of existing drugs,

they try to improve manufacturing processes.

Page 26: Bio Generics & India

26

Target Biologics Market Share & Patent Status

BiologicLeading Brand Company

Launch Year

Worldwide Sales 2006

(USD bn)

sales 2010 (USD Mn) EU

Market

US EU

Erythropoietin Epoitin alpha

and beta

Eprex/Procrit, Epogen,

Epogin/NeoRecormon

J&J, Amgen, Roche

1988 (alpha),

1990 (beta)

2014 (alpha),

n/a (beta)

Expired (alpa &

beta)13 701

G-CSF Neupogen Amgen 1991 2008 Expired 5.6 605

Interferon alpha

Intron, Roferon

Schering Plough, Roche

1987 Expired Expired 2.3188

(EU+US)

Interferon beta

Avonex, Rebif,

Betaferon

Biogen Idec,

Serono

1996 (1a) 1993(1b)

2008-2013 (1a)

Expired(1b)

2012 (1a)

Expired (1b)

3.7 131

Human growth hormone

Genotropin, Norditropin, Humantrope and others

Pfizer, Novo

Nordisk, Lilly and Others

1988 Expired Expired 1.9442

(EU+US)

Patent Expiry

Page 27: Bio Generics & India

27

Biogeneric Manufacturers and Their Products

Company Launched Biosimilars In the PipelineBarr EPO scheduled for launch in

Eastern EuropeG-CSF (Filgastrim), Insulin, and HGH

Biocon

Insugen (Insulin in India and China), Erypro (EPO) G-CSF, Nimotruzmab, BIOMAb EGFR

Insulin, glargine and HGH

Biopartners

Valtropin (rHGH) Alpheon (INF-α) and EPO

Cipla

None Autoimmune, cancer and cardiovascular

Dr. Reddy’s G-CSF (Filgastrim) Nine (9) development Glenmark None GBR 500 (mAb for MS),

GBR600 (antithrombotic) and mAbs for adhesion molecular inhibitors

Intas Biopharma Neukine (G-CSF), Erykine (EPO) and Intalfa (INF-alpha2b)

Six (6) development programs

Prolong Pharmaceuticals

None PEG-EPO and other PEGylated proteins

Page 28: Bio Generics & India

28

Biogeneric Manufacturers and Their Products

Company Launched Biosimilars In the PipelineRanbaxy Nugraf (Filgrastim), Macrogen

(Molgramostim from Zenotech)mAbs in oncology and neurology

Sandoz Omnitrope (HGH), Binocrit (EPO) Six (6) development programs including G-CSF (Filgrastim)

Shanta Biotechnics

Shaferon (INF-alpha2b, Shankinase (streptokinase) and Shanpoietin (EPO)

mAbs and PEGylated therapeutic proteins

Stada

EPO-Zeta (approved) Filgrastim

Teva

G-CSF (Filagstrim),Teva-Tropin (HGH), INF-alpha2b

Insulin, EPO and interleukins

Wockhardt

Wepo (EPO), Wosulin (insulin) INF-alpha2b, G-CSF

Insulin Glargine

These companies have already introduced as many as seven biotech drugs (Hepatitis B vaccine, Streptokinase, Insulin, G-CSF, Erythropoietin, Human Growth Hormone and Interferon alpha 2b) under many brands.

Page 29: Bio Generics & India

29

Sustain Biogenerics Market

Developing a specific bio-generic regulatory framework.

With the introduction of TRIPS agreement from January 1, 2005, Indian bio-generic companies should not concentrate on generating mere copies of the existing drugs, but try to improve manufacturing procedures, which may themselves bring new patents.

Modifying the patent framework to suit the bio-generic products.

Improving the approaches of generic suppliers from directly copying the drugs to generating novel targets (especially, applicable to bio-generic companies in Indian and other developing countries).

Policies from the originators

Customer receptivity towards biogeneric products

Page 30: Bio Generics & India

30

Core competencies that biosimilarcompanies need to survive

Traditional Generics World

Patent LawRegulatoryExpertiseLow Cost

Manufacture

Marketing

Clinical Trial

Design

Pharmacovigilance

Biologics

manufacture

Detailing to Specialists

Page 31: Bio Generics & India

31

EU has guidelines in place for approval of biosimilars, US and Japan lag behind in the process.

Biogenerics -Regulatory

Page 32: Bio Generics & India

32

US Approval Process for BiologicsThere are two distinct regulatory pathways for biologics are associated with a different set of barriers for approval of biosimilars.

Biologic License Application (BLA)

Approval Process for Biologics

Governed by Public Health Service Act (PHSA)

Approval pathway for the majority ofbiologics (e.g. epoetins, interferons, colony stimulating factors)

No abbreviated pathway for approval ofGenerics

New Drug Application (NDA)

Governed by Federal Food, Drug and Cosmetic Act (FFDCA)

Approval pathway for human growth hormone and insulin products

Hatch-Waxman provisions provide an abbreviated new drug application (ANDA) pathway for generic small molecule drugs

Section 505(b)(2) provides an abbreviated pathway for biosimilar approval

No existing statutory framework for approval of biosimilars

Page 33: Bio Generics & India

33

EU Approval Process for BiosimilarsEurope has a unified regulatory process for approval of Biosimilar:

European Medicines Agency (EMEA)

Committee for Medicinal Products for Human Use (CHMP)

•Reviews marketing authorization applications for biologics

•Awards either a ‘positive’ or ‘negative’ opinion based on evaluation of quality, safety and efficacy measures

EMEA has authority to recommend approval of biosimilars

European Commission (EC)

•After a product receives a positive opinion, the EC will grant marketing authorization valid for the European Union

Final decision-maker for marketing approval of biosimilars

Page 34: Bio Generics & India

34

Regulations on Biogenerics in India

Institutional BioSafety Committee (IBSC)

Review Committee on Genetic Manipulation

(RCGM)

Genetic Engineering Approval Committee

(GEAC)

Page 35: Bio Generics & India

35

Indigenous product development, manufacture & marketing of

pharmaceutical products derived from LMOs but the end product is

not an LMO.

Report of the task force on Recombinant Pharma, 2005

Page 36: Bio Generics & India

36

RCGM(Recommends human CT)

Application

IBSC IBSC

RCGM(Approves pre-clinical studies)

RCGM(Approves pre-clinical studies)

Pre-clinical trial conducted Pre-clinical trial conducted

RCGM(Recommends human CT to DCGI &

forwards views on containment facilities to GEAC)

GEAC examines information on containment facilities & data on clinical trials

DCGI (Approves Human CT)

Human CT Conducted

DCGI(Approves manufacture & market

authorization under Drug & Cosmetic rules based on the clinical trials data)

DCGI – Post Release Monitoring

Proto

col -

I

Environmental Clearance under Rule 1989 of EPA based on risk & benefit analysis and inform DCGI

DCGI(Approves manufacture &

market authorization under Drug & Cosmetic rules based

on the clinical trials data)

DCGI – Post Release Monitoring

DCGI (Approves Human CT)

Human CT Conducted

Risk Group

III & above

Risk Group

I & II

Page 37: Bio Generics & India

37

Trends In Biopharmaceuticals

Page 38: Bio Generics & India

38

Thank You

* Information presented here is available in public domain.